4 recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 4 |
| Phase 2 | 1 | Recruiting 1 |
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 242 | 2020-01-09 | 2025-11-05 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy Edetate Calcium Disodium, Multivitamin, Succimer - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 58 | 2018-10-11 | 2026-09-18 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Myelodysplastic Syndromes (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Myelomonocytic, Juvenile (1) · Lymphoma (1)
Bone Marrow Diseases (4) · Carcinogenesis (4) · Cell Transformation, Neoplastic (4) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3)
Edetic Acid (1) · Geritol (1) · Pentetic Acid (1) · Succimer (1) · blinatumomab (1) · ponatinib (1)
Ascentage Pharma Group Inc. (1) · Fred Hutchinson Cancer Center (1) · Incyte Biosciences International Sàrl (1) · M.D. Anderson Cancer Center (1)
United States (3) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Elizabeth Krakow (1) · Maro Ohanian (1) · Mohammed-El-Amine Bensmaine, MD (1) · Yifan Zhai, MD, PhD (1)
PMID 35982483, PMID 38683966, PMID 39570620
2018 (1), 2023 (1)